AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1991216
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrocortisone
Trial: 11053073
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses or long acting triamcinolone
Trial: 24469238
Drug: 2-year oral
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-year oral health fluoride varnish-oral health promotion intervention
Trial: 22846371
Drug: Nizatidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (300 mg/day) for 4 weeks
Trial: 17658395
Drug: Late intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late intensification course (high-dose cytarabine and methotrexate)
Trial: 17658395
Drug: Hybrid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid treatment protocol
Trial: 10613649
Drug: Recombinant factor
RxNorm normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant factor VIII (Recombinate) at a dose of 50 IU/kg
Trial: 1375679
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg oral dose)
Trial: 29171140
Drug: GAD-Alum (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-Alum (20 μg, 2 injections, 30 days apart)
Trial: 22834281
Drug: Glutamine (20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (20% solution N(2)‐L‐alanine‐L‐glutamine, 'Dipeptiven' Fresenius Kabi, Germany); 0.4 g/kg/day
Trial: 11870934
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 100 mg only (G1)
Trial: 11870934
Drug: Heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin infusion followed by 6 months of oral anticoagulation with coumadin (G2)
Trial: 10563540
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pantoprazole od
Trial: 10563540
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole od
Trial: 7569589
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (started as early as 6 hours postoperatively)
Trial: 7569589
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding forbidden until spontaneous restoration of intestinal function
Trial: 6377801
Drug: progabide (24.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: progabide (24.3 mg/kg daily for 2 weeks)
Trial: 28851055
Drug: Telmisartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (80 mg once per day)
Trial: 22149445
Drug: Control (ICP-targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (ICP-targeted therapy without prostacyclin)
Trial: 17636186
Drug: Low-intensity VKA
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity VKA treatment (target INR 2.5) plus aspirin (100 mg/day) for the first six months (Group A)
Trial: 17636186
Drug: Standard-intensity VKA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-intensity VKA treatment (target INR 3.7) (Group B)
Trial: 8678266
Drug: Thiopentone 4‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone 4‐6 mg/kg i.v., halothane 0.8‐1.5%, N2O‐‐O2 2:1, no opioids, droperidol 75 micrograms/kg i.v. (Group 1)
Trial: 8678266
Drug: Propofol 2‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2‐3 mg/kg i.v., propofol 6‐9 mg/kg.h, alfentanil 30 micrograms/kg.h, N2O‐O2 2:1, no antiemetics (Group 2)
Trial: 2354096
Drug: Suxamethonium after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium after sub-paralysing dose of tubocurarine (0.05 mg kg-1)
Trial: 2354096
Drug: Suxamethonium after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium after paralysing dose of atracurium (0.5 mg kg-1)
Trial: 2354096
Drug: Atracurium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.5 mg kg-1)
Trial: 2354096
Drug: Tubocurarine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine (0.05 mg kg-1)
Trial: 23347435
Drug: Intensive cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive cabergoline treatment (weekly increase by 1 mg per week followed by 4 weekly escalation)
Trial: 23347435
Drug: Conventional cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional cabergoline treatment (4 weekly escalation by 0.5 mg per week)
Trial: 19210150
Drug: Amlodipine/Olmesartan Medoxomil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/Olmesartan Medoxomil (AML/OM) 10/40 mg
Trial: 19210150
Drug: Amlodipine/Valsartan (AML/VAL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/Valsartan (AML/VAL) 10/320 mg
Trial: 9215826
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with methotrexate (30 mg/m2 on days 1, 15, and 22), vinblastine (3 mg/m2 on days 2, 15, and 22), doxorubicin (30 mg/m2 on day 2), and cisplatin (70 mg/m2 on day 2)
Trial: 9215826
Drug: Single‐agent cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐agent cisplatin (70 mg/m2 on day 1)
Trial: 29667217
Drug: False-positive digital
RxNorm normalized name: ALLERGENIC EXTRACT, FALSE RAGWEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: False-positive digital rectal exam (DRE)
Trial: 25895964
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene and dietary counseling
Trial: 25895964
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene and fluoride varnish application at 4, 8, and 12 months
Trial: 25895964
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene and tooth mousse applied by parents twice a day for 12 months
Trial: 23086138
Drug: TAK-875 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 6.25 mg
Trial: 23086138
Drug: TAK-875 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 12.5 mg
Trial: 23086138
Drug: TAK-875 25
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 25 mg
Trial: 23086138
Drug: TAK-875 50
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 50 mg
Trial: 23086138
Drug: TAK-875 200
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 200 mg
Trial: 18669462
Drug: Amifostine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (600 mg/m2/dose) administered as a bolus immediately before and 3 hours into the cisplatin infusion
Trial: 14607206
Drug: Moxonidine SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine SR (1.5 mg BID)
Trial: 8686973
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (low-dose lamivudine group)
Trial: 8686973
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (high-dose lamivudine group)
Trial: 8686973
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg of zalcitabine plus 200 mg of zidovudine three times daily (zalcitabine group)
Trial: 8686973
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of lamivudine plus zidovudine
Trial: 8686973
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of lamivudine plus zidovudine
Trial: 6337710
Drug: BCNU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCNU plus high-dose methylprednisolone
Trial: 29216820
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion at 0.2 μg·kg-1·hr-1
Trial: 29216820
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion at 0.5 μg·kg-1·hr-1
Trial: 29216820
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion at 0.8 μg·kg-1·hr-1
Trial: 29216820
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (0.2, 0.5, 0.8 μg·kg-1·hr-1)
Trial: 29216820
Drug: Low-dose infusion
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose infusion of sufentanil
Trial: 26719230
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg) added to 500 mg/m² pemetrexed and 75 mg/m² cisplatin (PCB)
Trial: 24995954
Drug: Butamirate (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butamirate (various doses)
Trial: 18332267
Drug: Vernakalant (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vernakalant (3 mg/kg for 10 minutes, followed by 2 mg/kg 15 minutes later if AF was not terminated)
Trial: 16116152
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with stem-cell rescue
Trial: 16116152
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (for infants)
Trial: 16116152
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy
Trial: 7495598
Drug: Self-administered survey
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered survey about risk factors for HIV infection
Trial: 2249115
Drug: Oxybutynin hydrochloride
RxNorm normalized name: Oxybutynin hydrochloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin hydrochloride (3 mg)
Trial: 7357798
Drug: Levodopa, 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa, 1,000 mg
Trial: 7357798
Drug: Levodopa, 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa, 1,000 mg and Metoclopramide, 10 mg
Trial: 20037568
Drug: Carbamazepine (CBM)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBM) 300-1600 mg/day (mean 700±120 mg/day) for 25.43±2.34 months
Trial: 20037568
Drug: Oxcarbazepine (OCB)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OCB) 600-1800 mg/day (mean 900±145 mg/day) for 12±0.65 months
Trial: 17324224
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg levetiracetam
Trial: 17324224
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg levetiracetam
Trial: 15505444
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at a target concentration of 3 microg/ml
Trial: 9768800
Drug: Propofol plus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol plus alfentanil 50 ng/mL
Trial: 9768800
Drug: Propofol plus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol plus alfentanil 100 ng/mL
Trial: 21700302
Drug: Standard low-fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard low-fat diet with daily walking (control)
Trial: 9083908
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily (days 0-28) plus amoxycillin 500 mg three times daily (days 15-28)
Trial: 8472521
Drug: ST-679 (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST-679 (1200 mg single oral dose)
Trial: 8472521
Drug: Paracetamol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1000 mg single oral dose)
Trial: 3704665
Drug: Myelosuppressive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myelosuppressive agents (32P or chlorambucil) supplemented by phlebotomy
Trial: 24045030
Drug: Cocaine, cannabis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine, cannabis, cigarettes, alcohol use, unintentional overdose, injection drug use
Trial: 19083391
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (250 mL daily for 4 weeks)
Trial: 19083391
Drug: Apple juice
RxNorm normalized name: apple juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple juice (250 mL daily for 4 weeks)
Trial: 12614835
Drug: group‐based cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group‐based cognitive‐behavioral stress management/expressive‐supportive therapy intervention (CBSM+)
Trial: 10852273
Drug: Corticosteroid injections
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injections (40 mg of 6‐methylprednisolone acetate)
Trial: 27931257
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral health program (without fluoride varnish)
Trial: 24666361
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin cream 0.1%
Trial: 11732859
Drug: T/T genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T/T genotype of the 5-HT2A receptor gene
Trial: 11732859
Drug: C/C and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/C and C/T genotypes of the 5-HT2A receptor gene
Trial: 2891519
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment (LH‐RH, LH‐RH plus hCG)
Trial: 27314247
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract (PAC‐Aproanthocyanidin‐A), 36 patients, administered for 12 weeks
Trial: 27314247
Drug: Placebo, 36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 36 patients, administered for 12 weeks
Trial: 18853053
Drug: Prilocaine 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine 3% associated with felypressin 0.03 IU/ml
Trial: 16801691
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Air-Stirrup brace, elastic wrap, walking cast)
Trial: 12891281
Drug: Atorvastatin (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (combined 10 mg and 40 mg)
Trial: 1593412
Drug: Pulsated jet
RxNorm normalized name: ABG Pulsator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsated jet irrigator with saline solution
Trial: 1593412
Drug: Syringe with
RxNorm normalized name: BD Syringe with Cannula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe with saline solution
Trial: 30728061
Drug: Citrus Aurantium
RxNorm normalized name: Citrus aurantium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus Aurantium + Caffeine (CA + C) 100 mg of CA and 100 mg of C
Trial: 27434441
Drug: Buprenorphine implants
RxNorm normalized name: buprenorphine Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine implants (80 mg, 4 implants)
Trial: 27434441
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (8 mg/d or less) with placebo implants
Trial: 22241281
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg amisulpride
Trial: 22241281
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg aripiprazole
Trial: 15569821
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) 10 microg/kg per day for 5 days
Trial: 12572702
Drug: Low-dose spiral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spiral computed tomography (CT) screening
Trial: 12572702
Drug: Neo-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant chemotherapy before surgery
Trial: 10469812
Drug: Prescription for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription for 2 quarts of ORS filled for free at on-site pharmacy plus written instructions
Trial: 1859751
Drug: Neostigmine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.1 mg kg‐1
Trial: 1859751
Drug: Neostigmine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.05 mg kg‐1 (control group)
Trial: 1859751
Drug: Doubling doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling doses of anticholinesterases
Trial: 27989618
Drug: 45-mg sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45-mg sustained-release pelubiprofen
Trial: 27989618
Drug: 75-mg sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg sustained-release eperisone hydrochloride
Trial: 26390073
Drug: Control Auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Auricular Point Acupressure (sham treatment), n = 15
Trial: 11473882
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil (160 +/- 32 microg)
Trial: 8037104
Drug: Enalapril, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 2.5 mg twice per day for 7 days (mean 6.1, range 2 to 7, median 7)
Trial: 8037104
Drug: Enalapril, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 2.5 mg twice per day
Trial: 17090988
Drug: Yakson therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yakson therapy (5 minutes of hand laying on the back and caressing the abdomen)
Trial: 12576164
Drug: 3.0 mg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg/kg/min infusion of valproate sodium injection
Trial: 12576164
Drug: 1.5 mg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg/min infusion of valproate sodium injection
Trial: 8913487
Drug: Atevirdine 600
RxNorm normalized name: Atevirdine
DrugBank: Atevirdine (DB12264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atevirdine 600 mg three times a day for 12 weeks
Trial: 28079755
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zeaxanthin per day
Trial: 28079755
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg zeaxanthin per day
Trial: 23478167
Drug: Active RPSS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active RPSS with daily motor training
Trial: 23478167
Drug: Sham RPSS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham RPSS with daily motor training
Trial: 17156423
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise (one-hour supervised session twice a week and daily home exercises)
Trial: 14660201
Drug: JTMT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTMT with the left hand (L)
Trial: 3533134
Drug: Nifedipine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (oral administration)
Trial: 3533134
Drug: Ritodrine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine (intravenous administration)
Trial: 29976161
Drug: Serial IV
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial IV bolus (6 g loading dose with 2 g bolus every 2 h using a Springfusor® pump)
Trial: 29976161
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (4 g loading dose with 1 g/hr. continuous infusion)
Trial: 26882922
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg × 3)
Trial: 26882922
Drug: Flurbiprofen (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (50 mg × 3)
Trial: 24253285
Drug: Norwalk virus
RxNorm normalized name: NORWALK VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norwalk virus (dosage for secretor-positive blood group O or A)
Trial: 24253285
Drug: Norwalk virus
RxNorm normalized name: NORWALK VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norwalk virus (dosage for all secretor-positive persons)
Trial: 20533760
Drug: Benzocaine lozenges
RxNorm normalized name: Benzocaine Lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine lozenges (8 mg), n = 123